International Assets Investment Management LLC Lowers Stock Holdings in Johnson & Johnson $JNJ

Key Points

• International Assets Investment Management LLC reduced its stock holdings in Johnson & Johnson by 19.0%, decreasing their position to 16,654 shares worth approximately $2.54 million.
• Multiple institutional investors have recently acquired shares of Johnson & Johnson, with institutional ownership now at 69.55%.
• Johnson & Johnson is set to pay a quarterly dividend of $1.30 on December 9th, representing a 2.7% yield, with a payout ratio of 50.19%.

International Assets Investment Management LLC reduced its position in Johnson & Johnson (NYSE:JNJ - Free Report) by 19.0% in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 16,654 shares of the company's stock after selling 3,904 shares during the quarter. International Assets Investment Management LLC's holdings in Johnson & Johnson were worth $2,544,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also bought and sold shares of the company. GFG Capital LLC purchased a new position in Johnson & Johnson during the second quarter worth about $35,000. Stone House Investment Management LLC bought a new stake in shares of Johnson & Johnson during the 1st quarter valued at about $47,000. 1248 Management LLC purchased a new position in shares of Johnson & Johnson during the first quarter worth about $48,000. von Borstel & Associates Inc. bought a new position in shares of Johnson & Johnson in the first quarter worth approximately $49,000. Finally, Harvest Fund Management Co. Ltd bought a new position in shares of Johnson & Johnson in the first quarter worth approximately $52,000. Institutional investors own 69.55% of the company's stock.

Wall Street Analyst Weigh In

JNJ has been the subject of several research analyst reports. Citigroup lifted their target price on shares of Johnson & Johnson from $213.00 to $215.00 and gave the company a "buy" rating in a research report on Wednesday, October 15th. Royal Bank Of Canada reaffirmed an "outperform" rating and set a $209.00 price objective on shares of Johnson & Johnson in a report on Friday, October 10th. Piper Sandler reissued an "overweight" rating on shares of Johnson & Johnson in a research note on Thursday, July 17th. Morgan Stanley set a $190.00 price target on Johnson & Johnson in a research report on Wednesday. Finally, Cowen reiterated a "buy" rating on shares of Johnson & Johnson in a report on Tuesday, October 14th. Two equities research analysts have rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and eight have given a Hold rating to the stock. According to data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $199.88.

Johnson & Johnson Price Performance

Shares of NYSE:JNJ opened at $193.27 on Monday. The company has a quick ratio of 0.76, a current ratio of 1.01 and a debt-to-equity ratio of 0.50. The stock has a market cap of $465.45 billion, a PE ratio of 18.65, a PEG ratio of 2.27 and a beta of 0.40. The company's fifty day moving average is $180.49 and its 200 day moving average is $164.90. Johnson & Johnson has a 52 week low of $140.68 and a 52 week high of $194.40.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last announced its quarterly earnings data on Wednesday, August 30th. The company reported $2.26 earnings per share (EPS) for the quarter. The firm had revenue of $24.02 billion for the quarter. Johnson & Johnson had a return on equity of 33.08% and a net margin of 27.26%. Research analysts anticipate that Johnson & Johnson will post 10.58 earnings per share for the current year.

Johnson & Johnson Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 9th. Shareholders of record on Tuesday, November 25th will be given a $1.30 dividend. The ex-dividend date is Tuesday, November 25th. This represents a $5.20 annualized dividend and a yield of 2.7%. Johnson & Johnson's payout ratio is presently 50.19%.

Insider Buying and Selling at Johnson & Johnson

In other news, EVP Jennifer L. Taubert sold 56,471 shares of the stock in a transaction that occurred on Thursday, September 4th. The stock was sold at an average price of $177.81, for a total transaction of $10,041,108.51. Following the completion of the sale, the executive vice president owned 178,013 shares of the company's stock, valued at approximately $31,652,491.53. This represents a 24.08% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Company insiders own 0.16% of the company's stock.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.